Funding
Opportunities
Directory
| Enhancing Mechanistic Research on Precision Probiotic Therapies (R61/R33 Clinical Trial Optional) | 01 Oct 2026 | $350,000/yr for 5 years | National Institutes of Health (NIH) | Early Career / Mid-Career | Click for detailsThe purpose of this notice of funding opportunity (NOFO) is to support highly innovative mechanistic research to accelerate the development of effective precision probiotic interventions using a milestone-driven, biphasic award mechanism. It aims to identify, understand, and develop strategies to address barriers in precision probiotic interventions to account for the heterogeneity in humans that often causes inconsistent probiotic therapeutic responses. Specifically, this NOFO solicits applications that will characterize person-specific features affecting probiotic responses to identify subgroups of probiotic responders, which may then help enhance probiotic clinical outcomes.The first phase, funded by the R61 mechanism, will provide 1 or 2 years of support to identify host biological patterns (e.g., native microbiome, immune system, sex, diet, age, genetic background, lifestyle, or health history) that are correlated with differences in probiotic clinical effects using observational or secondary data analysis studies. The second phase, funded under the R33 mechanism, will support studies to assess the causality of the factors identified in the R61 phase that impact probiotic responsiveness through rigorous mechanistic study designs in animal models or human subjects. This NOFO will not support efficacy or effectiveness clinical trials. |
| Enhancing Mechanistic Research on Precision Probiotic Therapies (R33 Clinical Trial Optional) | 01 Oct 2026 | $350,000/yr for 4 years | National Institutes of Health (NIH) | Early Career / Mid-Career | Click for detailsThe purpose of this notice of funding opportunity (NOFO) is to support highly innovative mechanistic research to accelerate the development of effective precision probiotic interventions. The NOFO aims to identify, understand, and develop strategies to address barriers in precision probiotic interventions' development to account for human heterogeneity resulting in inconsistent responses to probiotic treatments. Specifically, this NOFO solicits R33 applications that will assess the causality of person-specific features or patterns affecting probiotic responses and identify subgroups of probiotic responders in order to enhance therapeutic outcomes.This NOFO will support studies that assess whether host biological patterns (e.g., native microbiome, immune system, sex, diet, age, genetic background, lifestyle, or health history) that are correlated with clinical probiotic effects can modulate responsiveness to probiotic interventions. Well-suited applications must offer rigorously designed mechanistic studies using relevant/innovative animal models or human subjects. This NOFO is intended to support projects where potential host biological patterns that are correlated with probiotic usage or interventions have been identified, as demonstrated with supportive preliminary data, which require further mechanistic studies to test for causality. This NOFO will not support efficacy or effectiveness clinical trials. |
| Limited Competition: NIGMS Mature Synchrotron Resources (MSR) for Structural Biology (P30 - Clinical Trial Not Allowed) | 02 Oct 2026 | varies to reflect the needs of the project | National Institutes of Health (NIH) | Early Career / Mid-Career |
Click for detailsThis Notice of Funding Opportunity (NOFO) supports "mature" resources at synchrotron facilities that provide user access to X-ray beamlines for static and dynamic imaging of biological systems ranging from molecules to organs. "Mature" refers to the techniques made available at the resource beamlines, which must be well established and provide utility to the communities they serve without requiring significant novel technology development. Applications may only request support for existing synchrotron resources that are currently supported by NIGMS funding. The facility is expected to be maintained or upgraded to current best practices, make its capabilities and availability known to the biomedical research community through outreach activities, and provide user training and support. |
| Basic Research in Cancer Health Disparities (R01 Clinical Trial Not Allowed) | 05 Oct 2026 | varies to reflect the needs of the project | National Institutes of Health (NIH) | Early Career / Mid-Career |
Click for detailsThis Notice of Funding Opportunity (NOFO) encourages grant applications from investigators interested in conducting basic, mechanistic research into the biological/genetic causes of cancer health disparities. These research project grants (R01) will support innovative studies designed to investigate biological/genetic contributors of cancer health disparities, such as (1) mechanistic studies of biological factors associated with cancer health disparities, including those related to basic research in cancer biology or cancer prevention strategies, (2) the development and testing of new methodologies and models, and (3) secondary data analyses. This NOFO is also designed to aid and facilitate the growth of a nationwide cohort of scientists with a high level of basic research expertise in cancer health disparities research who can expand available resources and tools, such as biospecimens, patient derived models, and methods that are necessary to conduct basic research in cancer health disparities. |
| Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (R01 Clinical Trial Optional) | 05 Oct 2026 | $500,000/yr for 2 years | National Institutes of Health (NIH) | Early Career / Mid-Career |
Click for detailsThrough this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to stimulate translation of scientific discoveries and engineering developments in imaging, data science and/or spectroscopic technologies into methods or tools that address contemporary problems in understanding the fundamental biology, potential risk of development, diagnosis, or treatment of cancer. A distinguishing feature of each application to this NOFO will be formation of an academic-industrial partnership: a strategic alliance of academic and industrial investigators who work together as partners to identify and translate a technological solution for mitigation of a cancer (or other disease-related) problem. In this sense, the NOFO acts more as a funding mechanism for driving translational research in imaging than for a specific scientific or clinical research area. These partnerships are expected to solidify pre-existing collaborations or establish new ones that would drive the field of imaging, as a whole, further than if they had not been formed. This NOFO defines innovation as the likelihood to deliver a new capability to end users. This funding announcement will support clinical trials that test functionality or validate performance in the chosen setting. However, this NOFO is not intended to support commercial production, basic research projects, or clinical trials that lack translation as the primary motivation. |
| Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Optional) | 05 Oct 2026 | $499,000/yr for 5 years | National Institutes of Health (NIH) | Early Career / Mid-Career |
Click for detailsThe purpose of this Notice of Funding Opportunity (NOFO) Announcement is to stimulate efforts to translate scientific discoveries and engineering developments into methods or tools that address problems in basic research to understand disease, or in applied research to assess risk, detect, prevent, diagnose, treat, and/or manage disease. The rationale is to deliver new capabilities to meet evolving requirements for technologies and methods relevant to the advance of research and delivery of care in pre-clinical, clinical and non-clinical settings, domestic or foreign, for conditions and diseases within the missions of participating institutes.This NOFO specifies a partnership structure that is expected to help bridge gaps in knowledge and experience by engaging the strengths of academic, industrial, and other investigators. The partners on each application should establish an inter-disciplinary, multi-institutional research team to work in strategic alliance to implement a coherent strategy to develop and translate a solution to their chosen problem. They are expected to plan, design, and validate that the solution will be suitable for end users. Each partnership should include at least one academic and one industrial organization. Each partnership should plan to transition a technology, method, assay, device, and/or system from a demonstration of possibility to a status useful in the chosen setting. Funding may be requested to enhance, adapt, optimize, validate, and otherwise translate technologies that address problems in biology, pathology, risk assessment, diagnosis, treatment, and/or monitoring of disease status. |
| Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Not Allowed) | 05 Oct 2026 | $499,000/yr for 5 years | National Institutes of Health (NIH) | Early Career / Mid-Career |
Click for detailsThe purpose of this Notice of Funding Opportunity (NOFO) is to stimulate efforts to translate scientific discoveries and engineering developments into methods or tools that address problems in basic research to understand disease, or in applied research to assess risk, detect, prevent, diagnose, treat, and/or manage disease. The rationale is to deliver new capabilities to meet evolving requirements for technologies and methods relevant to the advance of research and delivery of care in pre-clinical, clinical and non-clinical settings, domestic or foreign, for conditions and diseases within the missions of participating institutes. This NOFO specifies a partnership structure that is expected to help bridge gaps in knowledge and experience by engaging the strengths of academic, industrial, and other investigators. The partners on each application should establish an inter-disciplinary, multi-institutional research team to work in strategic alliance to implement a coherent strategy to develop and translate a solution to their chosen problem. They are expected to plan, design, and validate that the solution will be suitable for end users. Each partnership should include at least one academic and one industrial organization. Each partnership should plan to transition a technology, method, assay, device, and/or system from a demonstration of possibility to a status useful in the chosen setting. Funding may be requested to enhance, adapt, optimize, validate, and otherwise translate technologies that address problems in biology, pathology, risk assessment, detection, diagnosis, treatment, and/or monitoring of disease status. This NOFO defines "innovation" as likelihood to deliver a new capability to end users. |
| Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional) | 05 Oct 2026 | $250,000/yr for 5 years | National Institutes of Health (NIH) | Early Career / Mid-Career |
Click for detailsThis notice of funding opportunity (NOFO) encourages applications for research in cancer control and population sciences. The overarching goal is to provide support to promote research efforts on novel scientific ideas that have the potential to substantially advance cancer research in statistical and analytic methods, epidemiology, cancer survivorship, cancer-related behaviors and behavioral interventions, health care delivery, digital health and data science, and implementation science. |
| Molecular Imaging of Inflammation in Cancer (R01 Clinical Trial Not Allowed) | 05 Oct 2026 | $500,000/yr for 2 years | National Institutes of Health (NIH) | Early Career / Mid-Career |
Click for detailsThrough this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites research grant applications (R01) for the development and application of current and emerging molecular imaging methods to gain fundamental insights into cancer inflammationin vitro. The motivation for this initiative is the recognition that much of the current imaging research on inflammation in cancer relies heavily onin vitroandex vivomethods. These approaches have limited potential to provide significant insights into the dynamic interactions between cancer and inflammation. Utilizing molecular imaging probes in pre-clinical and clinical investigations allows for precise temporal resolution at molecular and cellular levels. This information is valuable for identifying and characterizing in vivo inflammatory cellular physiology in cancer and for detecting molecular changes in response to treatment. This NOFO encourages applications focused on developing integrated imaging approaches to investigate the role of inflammation in cancer through strong cross-discipline collaboration between cancer basic science researchers and imaging scientists. These collaborations are expected to advance the science and understanding of cancer inflammation interactions. |
| Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional) | 05 Oct 2026 | varies to reflect the needs of the project | National Institutes of Health (NIH) | Early Career / Mid-Career |
Click for detailsThe purpose of this Notice of Funding Opportunity (NOFO) is to promote research studies designed to address adverse sequelae of cancer therapies that persist and become chronic co-morbidities or develop as delayed posttreatment effects. This NOFO supports basic, translational, and clinical research projects that seek to identify the mechanisms of therapy-induced adverse sequelae, clinically characterize the adverse sequelae, and translate the mechanistic understanding into therapeutic approaches to prevent or minimize the development of long-term sequelae. The scope of research projects includes mechanistic studies with translational endpoints and longitudinal clinical phenotyping to identify and validate clinical endpoints (biomarkers, imaging, patient-reported outcomes or combined elements) for future use in clinical trials that will evaluate the efficacy of interventions designed to prevent or reduce specific adverse sequelae. |
| The Metastasis Research Network (MetNet): MetNet Research Projects (U01 Clinical Trial Not Allowed) | 05 Oct 2026 | $500,000/yr for 5 years | National Institutes of Health (NIH) | Early Career / Mid-Career |
Click for detailsThe National Cancer Institute's (NCI) Metastasis Research Network (MetNet) is a collection of U54 Research Centers that support using systems-level approaches to understand pressing questions in metastasis. The overall goal of the MetNet is to advance our understanding of metastasis as a whole body, systems-level problem to develop a comprehensive and cohesive picture of the processes involved. Through this Notice of Funding Opportunity (NOFO), the NCI invites applications for MetNet Research Projects. These Research Projects should be defined as discrete entities that use systems-level approaches to address gaps and opportunities in metastasis research to integrate into the MetNet and complement ongoing research across the Network. |
| Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional) | 05 Oct 2026 | varies to reflect the needs of the project | National Institutes of Health (NIH) | Early Career / Mid-Career |
Click for detailsThrough this notice of funding opportunity (NOFO), the National Cancer Institute (NCI) invites applications for investigator-initiated studies addressing mechanisms by which incretin mimetics, specifically glucagon-like peptide (GLP)-1 or dual GLP-1/ glucose-dependent insulinotropic polypepide (GIP)-1 receptor agonists (RAs), impact cancer risk. The focus on these agents is due to their reported effects on thyroid, prostate and other cancer risks, and the generally more favorable efficacy and side effect profile compared to other classes of incretin mimetics. In addition, this NOFO seeks to draw in talented scientists to the cancer biology field who may study incretin mimetic effects on diseases other than cancer. Investigators wishing to study incretin mimetics other than GLP-1 RAs or GLP-1/GIP-1 RAs, such as dipeptidyl peptidase (DPP)-4 inhibitors, must justify why the agent(s) they propose to study are more effective and/or have a more favorable side effect profile than GLP-1 or GLP-1/GIP-1 RAs. Route of agent administration (oral vs. other) is, by itself, not an adequate justification. |
| Interventions to Address Disparities in Liver Diseases and Liver Cancer (R01 - Clinical Trials Optional) | 05 Oct 2026 | varies to reflect the needs of the project | National Institutes of Health (NIH) | Early Career / Mid-Career |
Click for detailsThis initiative will support multi-level and/or multi-domain intervention research to reduce disparities in liver diseases and liver cancer among populations who experience health disparities in the United States (U.S.). |
| Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01 Clinical Trial Not Allowed) | 09 Oct 2026 | varies to reflect the needs of the project | National Institutes of Health (NIH) | Early Career / Mid-Career |
Click for detailsThrough this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) encourages the submission of applications that propose to advance research in cancer etiology and early detection biomarkers, utilizing the advantages of the unique biorepository resources of the NCI-sponsored Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Screening Trial. The PLCO Biorepository offers high-quality, prospectively collected, serial pre-diagnostic blood samples from the PLCO screened arm participants, and buccal cells from both the screened and the control arm participants. Available data associated with the biospecimens includes demographic, diet, lifestyle, smoking, screening results, and other clinical data. This NOFO supports a wide range of cancer research including, but not limited to, biochemical and genetic analyses of cancer risk, as well as discovery and validation of early detection biomarkers. The proposed research project must involve use of PLCO biospecimens and may include other resources; additionally, it should also take advantage of the unique characteristics of the PLCO biospecimens. Research on non-cancer outcomes, especially those related to aging (e.g., Alzheimer’s, depression, hip fracture, osteoporosis and rheumatoid arthritis) may also be supported. Research projects that do not involve the use of PLCO biospecimens will not be supported under this NOFO. |
| Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01 Clinical Trial Not Allowed) | 10 Feb 2027 | varies to reflect the needs of the project | National Institutes of Health (NIH) | Early Career / Mid-Career |
Click for detailsThrough this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) encourages the submission of applications that propose to advance research in cancer etiology and early detection biomarkers, utilizing the advantages of the unique biorepository resources of the NCI-sponsored Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Screening Trial. The PLCO Biorepository offers high-quality, prospectively collected, serial pre-diagnostic blood samples from the PLCO screened arm participants, and buccal cells from both the screened and the control arm participants. Available data associated with the biospecimens includes demographic, diet, lifestyle, smoking, screening results, and other clinical data. This NOFO supports a wide range of cancer research including, but not limited to, biochemical and genetic analyses of cancer risk, as well as discovery and validation of early detection biomarkers. The proposed research project must involve use of PLCO biospecimens and may include other resources; additionally, it should also take advantage of the unique characteristics of the PLCO biospecimens. Research on non-cancer outcomes, especially those related to aging (e.g., Alzheimer’s, depression, hip fracture, osteoporosis and rheumatoid arthritis) may also be supported. Research projects that do not involve the use of PLCO biospecimens will not be supported under this NOFO. |
| Development and Testing of a Multi-use Frameworks Playbook for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U01 Clinical Trial Not Allowed) | 09 Oct 2026 | $300,000/yr for 2 years | National Institutes of Health (NIH) | National Institutes of Health |
Click for detailsThe purpose of this NOFO is to solicit applications for the design, development, and preliminary validation of robust frameworks for the application of multimodal-artificial intelligence (AI) models for clinical use. Frameworks developed through these awards would populate a "playbook", defined as a collection of actionable guidelines, standardized protocols, and/or standard operating procedures (SOPs) for reliable and effective development and deployment of multimodal AI tools. It is expected that the frameworks delineated in this playbook will directly address PRIMED-AI objectives and needs, while also remaining flexible enough to enable sufficient extensibility and interoperability for use across a broad spectrum of multimodal biomedical AI applications, both internal and external to the PRIMED-AI Program. |
| Institutional Mentored Career Development Award (Parent K12) (Clinical Trials Not Allowed) | 12 Oct 2026 | varies to reflect the needs of the project | National Institutes of Health (NIH) | Early Career / Mid-Career |
Click for detailsThe National Institutes of Health (NIH) invite applications for the Institutional Mentored Career Development grants. These support career development programs designed to prepare later stage postdoctoral fellows and junior faculty scholars who have made a commitment to an independent research career for their career advancement and transition to independence. Supported scholars will have "protected time" to engage in intensive, mentored research career development experiences in the fields of biomedical and behavioral research. |
| Paul Calabresi career development award for clinical oncology (K12 clinical trial optional) | 12 Oct 2026 | $50,000 - $750,000/yr for 5 years | National Institutes of Health (NIH) | Mid-Career to Established in Field |
Click for detailsThe goal of the Paul Calabresi Career Development Award for Clinical Oncology (PCACO) is to increase the number of clinician-scientists trained in clinical and translational cancer research, and to promote their career development as cancer researchers. |
| NHLBI Career Transition Award for Intramural Postdoctoral Fellows and Research Trainees (K22 Independent Clinical Trial Not Allowed) | 12 Oct 2026 | varies to reflect the needs of the project | National Institutes of Health (NIH) | Early Career and Emerging in Field |
Click for detailsThe purpose of the NHLBI Career Transition Award (K22) program is to provide highly qualified postdoctoral fellows and other doctoral-level researchers currently in training in the NHLBI Division of Intramural Research with the opportunity to transition their research programs to extramural institutions as junior investigators. To achieve these objectives, the NHLBI Career Transition Award will support two phases of research: a mentored intramural phase (up to two years) and an extramural phase (three years), for a total of five years of combined support. Transition from the intramural phase of support to the extramural phase is not automatic. Approval of the transition will be based on the success of the awardee's research program during the mentored phase as determined by an NHLBI progress review, which will include an evaluation of a research plan to be carried out at the extramural institution. |
| Stimulating Access to Research in Residency (StARR) (R38 Independent Clinical Trial Not Allowed) | 13 Oct 2026 | varies to reflect the needs of the project | National Institutes of Health (NIH) | Mid-Career to Established in Field |
Click for detailsThe purpose of this program is to recruit and retain outstanding, postdoctoral-level health professionals who have demonstrated potential and interest in pursuing careers as clinician-investigators. To address the growing need for this critical component of the research workforce, this funding opportunity seeks applications from institutional programs that can provide outstanding mentored research opportunities for Resident-Investigators and foster their ability to transition to individual career development research awards. The program will support institutions to provide support for up to 2 years of research conducted by Resident-Investigators in structured programs for clinician-investigators with defined program milestones. To accomplish the stated over-arching goal, this NOFO will support educational activities with a primary focus on:Courses for Skills Development,Research Experiences,Mentoring Activities, andCurriculum or Methods Development. |
| NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00 - Independent Clinical Trial Not Allowed) | 14 Oct 2026 | varies to reflect the needs of the project | National Institutes of Health (NIH) | Early Career and Emerging in Field |
Click for detailsThe purpose of the NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00) program is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. This program is designed for postdoctoral fellows with research and/or clinical doctoral degrees who do not require an extended period of mentored research training beyond their doctoral degrees. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent tenure-track (or equivalent) faculty positions. The program will provide independent NCI research support during this transition to help awardees launch competitive, independent research careers. Researchers in the scientific areas of cancer control, cancer prevention and cancer data sciences are especially encouraged to work with their institutions to apply. |
| NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00 - Independent Clinical Trial Required) | 14 Oct 2026 | varies to reflect the needs of the project | National Institutes of Health (NIH) | Early Career and Emerging in Field |
Click for detailsThe purpose of the NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00) program is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. This program is designed for postdoctoral fellows with research and/or clinical doctoral degrees who do not require an extended period of mentored research training beyond their doctoral degrees. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent tenure-track (or equivalent) faculty positions. The program will provide independent NCI research support during this transition to help awardees launch competitive, independent research careers. Researchers in the scientific areas of cancer control, cancer prevention and cancer data sciences are especially encouraged to work with their institutions to apply. |
| Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Trials Not Allowed) | 14 Oct 2026 | $250,000/yr for 3 years | National Institutes of Health (NIH) | Early Career / Mid-Career |
Click for detailsThrough this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to accelerate the adoption and validation of molecular/cellular/imaging markers (referred to as "markers" or "biomarkers") and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control. This NOFO will also support the validation of pharmacodynamic markers and markers of toxicity. Applicants to this NOFO must have an assay(s) whose performance has been analytically validated in specimens similar to those for the intended clinical use of the marker(s) and assay(s). As chemotherapies and/or radiation therapies are increasingly combined with immunotherapies to enhance the durability of anti-cancer responses, assays for measuring multiple markers, including immune markers, can be developed and validated simultaneously.The UH3 mechanism will support the clinical validation of established assays for up to 3 years using specimens from retrospective or prospective clinical trials or studies. This NOFO may be used to validate existing assays for use in other trials, observational studies, or population studies. Efforts to harmonize clinical laboratory tests, including investigation into the performance and reproducibility of assays across multiple clinical laboratories, are also appropriate for this funding opportunity. Projects proposed for this NOFO will require multidisciplinary interaction and collaboration among scientific investigators, oncologists, statisticians, and clinical laboratory scientists. This NOFO is not intended to support early-stage development of technology or the conduct of clinical trials but is intended for validation of assays to the point where they could be integrated into clinical trials/studies as investigational assays. |
| Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed) | 14 Oct 2026 | $275,000 over 2 years | National Institutes of Health (NIH) | Early Career / Mid-Career |
Click for detailsThrough this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites applications to support the validation of molecular/cellular/imaging markers (referred to as "markers" or "biomarkers") and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control. This NOFO will support investigator-initiated research for both analytical, and clinical validation of assays to be used in cancer treatment, control, or prevention trials supported by the NCI. This NOFO will also support the validation of pharmacodynamic markers and markers of toxicity. Applicants should have assays that work on human samples and whose importance is well justified for development into clinical assays. As chemotherapies and/or radiation therapies are increasingly combined with immunotherapies to enhance durability of anti-cancer responses, assays for measuring multiple markers, including immune markers, can be developed and validated simultaneously.The UH2 phase of this NOFO supports analytical validation of assays for these molecular/cellular/imaging markers, which must be achieved within 2 years before assays may undergo clinical validation. The UH3 phase of this NOFO supports clinical validation of analytically validated assays for up to 3 years using well-annotated biospecimens from retrospective or prospective clinical trials or studies. |
| NCI Pathway to Independence Award (K99/R00 Clinical Trial Required) | 14 Oct 2026 | varies to reflect the needs of the project | National Institutes of Health (NIH) | Early Career and Emerging in Field |
Click for detailsThe goal of the NCI Pathway to Independence Award (K99/R00) program is to facilitate a timely transition of talented postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help awardees to launch competitive, independent research careers. |
| NCI Pathway to Independence Award (K99/R00 Clinical Trial Not Allowed) | 14 Oct 2026 | varies to reflect the needs of the project | National Institutes of Health (NIH) | Early Career and Emerging in Field |
Click for detailsThe goal of the NCI Pathway to Independence Award (K99/R00) program is to facilitate a timely transition of talented postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help awardees to launch competitive, independent research careers. |
| Basic Research in Cancer Health Disparities (R21 Clinical Trial Not Allowed) | 16 Oct 2026 | $275,000 over 2 years | National Institutes of Health (NIH) | Early Career / Mid-Career |
Click for detailsThis Notice of Funding Opportunity (NOFO) encourages grant applications from investigators interested in conducting basic research studies into the biological/genetic causes and mechanisms of cancer health disparities. These awards will support pilot and feasibility studies designed to investigate biological/genetic contributors of cancer health disparities, such as (1) mechanistic studies of biological factors associated with cancer health disparities, (2) the development and testing of new methodologies and models, and (3) secondary data analyses. This NOFO is also designed to aid and facilitate the growth of a nationwide cohort of scientists with a high level of basic research expertise in cancer health disparities research who can expand available resources and tools, such as biospecimens, patient derived models and methods that are necessary to conduct basic research in cancer health disparities. In addition, the NOFO will further the development of scientific areas, providing support for early-stage exploratory projects that lead to future in-depth mechanistic studies (such as R01 projects) of the biology of cancer health disparities. |
| Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed) | 16 Oct 2026 | $275,000 over 2 years | National Institutes of Health (NIH) | Early Career / Mid-Career |
Click for detailsThrough this notice of funding opportunity (NOFO), the National Cancer Institute (NCI) invites applications for investigator-initiated studies addressing mechanisms by which incretin mimetics, specifically glucagon-like peptide (GLP)-1 or dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP)-1 receptor agonists (RAs), impact cancer risk. The focus on these agents is due to their reported effects on thyroid, prostate and other cancer risks, and the generally more favorable efficacy and side effect profile compared to other classes of incretin mimetics. In addition, this NOFO seeks to draw in talented scientists to the cancer biology field who may study incretin mimetic effects on diseases other than cancer. |
| Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Optional) | 16 Oct 2026 | $275,000 over 2 years | National Institutes of Health (NIH) | Early Career / Mid-Career |
Click for detailsThe purpose of this engineering-oriented notice of funding opportunity (NOFO) announcement is to encourage submissions of exploratory/developmental Bioengineering Research Grant (EBRG) applications to demonstrate feasibility and potential utility of new capabilities or improvements in quality, speed, efficacy, operability, costs, and/or accessibility of solutions to problems in basic biomedical, pre-clinical, or clinical research, clinical care delivery, or accessibility. This NOFO will support clinical trials that test functionality or validate performance in the chosen setting. Applications that propose phase III clinical trials are not sought by and will not be supported through this NOFO. |
| Developing novel theory and methods for understanding the genetic architecture of complex human traits (R21 Clinical Trial Not Allowed) | 16 Oct 2026 | $275,000 over 2 years | National Institutes of Health (NIH) | Early Career / Mid-Career |
Click for detailsThe goal of this NOFO is to support applications for novel theory and methods development that enable better understanding of how genetic and non-genetic factors contribute to complex trait variation across individuals, families, and populations. Approaches should account for interdependencies across scales of biological, social, and ecological organization, make extensive use of theory, modeling, and validation with available large-scale datasets, and may be interdisciplinary drawing from the natural and social sciences. |
| Mechanisms that Impact Cancer Risk after Bariatric Surgery (R21 Clinical Trial Not Allowed) | 16 Oct 2026 | $275,000 over 2 years | National Institutes of Health (NIH) | Early Career / Mid-Career |
Click for detailsThrough this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites applications for support of investigator-initiated studies addressing mechanisms by which bariatric surgery impacts cancer risk, and seeks to draw in talented scientists who study bariatric surgery to investigate its effects on cancer, rather than shorter-term outcomes such as weight loss and diabetes. The goal of this NOFO is to support proof of concept studies for feasibility and exploratory development. Feasibility must not have already been developed in the literature or with preliminary data. |
| Sustained Support for Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional) | 19 Oct 2026 | $600,000/yr for 5 years | National Institutes of Health (NIH) | Early Career / Mid-Career |
Click for detailsThis Notice of Funding Opportunity (NOFO) solicits applications for the continued development and sustainment of high value informatics research resources to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology. |
| Cancer Prevention and Control Clinical Trials Planning Grant Program (R34 Clinical Trials Optional) | 25 Oct 2026 | $450,000 - $600,000 over 3 years | National Institutes of Health (NIH) | Early Career / Mid-Career |
Click for detailsThrough this notice of funding opportunity (NOFO), the National Cancer Institute (NCI) intends to facilitate well planned clinical trials across the cancer prevention and control spectrum aimed at improving prevention/ interception, cancer-related health behaviors, screening, early detection, healthcare delivery, management of treatment-related symptoms, supportive care, and the long-term outcomes of cancer survivors. Although the scientific literature or preliminary data may provide the rationale for conducting a clinical trial, investigators often lack critical information about the study population, accrual challenges, intervention, outcome/ endpoints, data/statistical challenges or operational risks necessary to finalize the trial protocol completely. These information gaps can result in multiple protocol changes before and after trial start-up, leading to the need for additional time and expenses that may prevent study completion. Further, the suitability and feasibility of new trial designs, which minimize infrastructure and reduce costs may need to be tested in the context of a particular intervention, at-risk group, symptom or venue. Preparatory studies may fill information gaps and address unknowns this can include a pilot/feasibility clinical trial if necessary, improving trial design and rigor. |
| Cancer Prevention and Control Clinical Trials Planning Grant Program (U34 Clinical Trials Optional) | 25 Oct 2026 | $450,000 - $600,000 over 3 years | National Institutes of Health (NIH) | Early Career / Mid-Career |
Click for detailsThrough this notice of funding opportunity (NOFO), the National Cancer Institute (NCI) intends to facilitate well planned clinical trials across the cancer prevention and control spectrum aimed at improving prevention/ interception, cancer-related health behaviors, screening, early detection, healthcare delivery, management of treatment-related symptoms, supportive care, and the long-term outcomes of cancer survivors. Although the scientific literature or preliminary data may provide the rationale for conducting a clinical trial, investigators often lack critical information about the study population, accrual challenges, intervention, outcome/ endpoints, data/statistical challenges or operational risks necessary to finalize the trial protocol completely. These information gaps can result in multiple protocol changes before and after trial start-up, leading to the need for additional time and expenses that may prevent study completion. Further, the suitability and feasibility of new trial designs, which minimize infrastructure and reduce costs may need to be tested in the context of a particular intervention, at-risk group, symptom or venue. Preparatory studies may fill information gaps and address unknowns this can include a pilot/feasibility clinical trial if necessary, improving trial design and rigor. |
| Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools (R15 Clinical Trial Not Allowed) | 25 Oct 2026 | $375,000 over 3 years | National Institutes of Health (NIH) | Early Career / Mid-Career |
Click for detailsThe purpose of the Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools is to support small scale research grants at institutions that do not receive substantial funding from the NIH, with an emphasis on providing biomedical research experiences primarily for health professional, undergraduate and graduate students and enhancing the research environment at applicant institutions. |
| Clinical Microbiology Fellowship | 01 Nov 2026 | Fellowship | Memorial Sloan Kettering Cancer Center | Early Career and Emerging in Field |
Click for detailsThe Department of Laboratory Medicine at Memorial Sloan Kettering Cancer Center offers a two-year Clinical Microbiology Fellowship. This fellowship offers training for doctoral-level scientists interested in acquiring knowledge and skills necessary to direct a clinical microbiology laboratory. The fellowship will provide both general training in clinical microbiology as well as specialized training for diagnostic microbiology in immunocompromised patients. The fellow will obtain training in all subspecialties of clinical microbiology and develop knowledge of both conventional and molecular diagnostic methods for identification and antimicrobial susceptibility testing of bacteria, mycobacteria, fungi, and rapid detection of viruses and parasites. Additionally, the fellow will develop skills in laboratory management, clinical consultation related to microbiology and infectious diseases and interpretation, and clinical correlation of laboratory data. A strong emphasis is also placed on laboratory research, diagnostic assays development, and outcome studies in immunocompromised patients. |
| AAAS Science & Technology Policy Fellowships | 01 Nov 2026 | Fellowship | American Association for the Advancement of Science (AAAS) | Early Career / Mid-Career |
Click for detailsThe Science & Technology Policy Fellowships (STPF) program provides opportunities to outstanding scientists and engineers to learn first-hand about policymaking and contribute their knowledge and analytical skills in the policy realm. Fellows represent a broad range of backgrounds, disciplines, and career stages. Each year, STPF adds to a growing corps approximately 4,000 strong of policy-savvy leaders working across academia, government, nonprofits, and industry to serve the nation and citizens around the world. |
| U.S. National Science Foundation State and Regional Artificial Intelligence Infrastructure Hubs: Expanding Access to Compute for Scientific Discovery (AI Infrastructure Hubs) | 04 Nov 2026 | $4,000,000 - $12,000,000 | National Science Foundation (NSF) | Early Career / Mid-Career |
Click for detailsThe NSF State and Regional AI Infrastructure Hubs program aims to expand access to the compute required for AI-enabled scientific discovery and to transform the research, education, and training opportunities offered by institutions of higher education. AI Infrastructure Hubs will connect researchers to new compute infrastructure that leverages contributions from state governments, research institutions, industry, and philanthropy, accelerating AI-enabled discovery across science and engineering and developing a skilled technical workforce for AI use in the scientific enterprise. |
| Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed) | 10 Nov 2026 | $300,000/yr for 3 years | National Institutes of Health (NIH) | Early Career / Mid-Career |
Click for detailsThrough this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites grant applications proposing exploratory research projects focused on further development and technical validation of emerging technologies offering novel capabilities for the molecular or cellular characterization of cancer or for improved handling and quality control of biospecimens used for basic, clinical, or epidemiological cancer research. This NOFO solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still require further development and rigorous technical validation to encourage adoption by the research community. Well-suited applications must propose the development of technologies that offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, cancer control, epidemiology. Technologies proposed for development may have potential for widespread applicability but must be focused in this proposal on cancer-relevant use cases. |
| CRI Technology Impact Award | 16 Nov 2026 | 600,000/yr for 2-4 years | Technology Impact Award | Early Career / Mid-Career |
Click for detailsThe CRI Technology Impact Award is designed to support early-stage, pre-development concepts — innovations that have not yet been built or tested, but that hold the potential to transform the landscape of cancer immunotherapy.The CRI Technology Impact Award aims to bridge the gap between conceptual technological innovation and real-world clinical application. By encouraging collaboration between technology developers and clinical cancer immunologists, CRI hopes to accelerate the creation of technologies that can generate proof-of-principle data and unlock novel biological insights. |
| Toward Translation of Nanotechnology Cancer Interventions (TTNCI; R01 Clinical Trial Not Allowed) | 16 Nov 2026 | $475,000/yr for 4 years | National Institutes of Health (NIH) | Early Career / Mid-Career |
Click for detailsThis Notice of Funding Opportunity (NOFO), entitled "Toward Translation of Cancer Nanotechnology Interventions (TTNCI)" is designed to enable the translation of nanotechnology-based cancer interventions relying on nanoparticle formulations and/or nano-devices. Through the TTNCI initiative, the National Cancer Institute (NCI) encourages applications for advanced pre-clinical research, supporting translation of nanotechnology-based cancer diagnostics and therapeutics. TTNCI awards are expected to mature experimental nanomedicines designed for highly relevant cancer clinical objectives with a strong potential to improve cancer treatment effectiveness. It is expected that improvement of treatment effectiveness will occur due to the combination of nanoparticle/nano-device structural design and/or therapeutic/diagnostic cargo which is delivered. TTNCI awards are expected to enable further development of proposed nanotechnology-based interventions to the stage in which they could continue on a developmental path towards the NCI Experimental Therapeutics (NExT) and other NCI translational programs. |
| Competing Revisions to Existing NIH Grants and Cooperative Agreements (Clinical Trial Optional) | 24 Nov 2026 | varies to reflect the needs of the project | National Institutes of Health (NIH) | Early Career / Mid-Career |
Click for detailsThe National Institutes of Health (NIH) hereby notifies NIH award recipients that funds may be available for revision applications to support the expansion of existing projects and/or programs within the awarding Institute or Center (IC) identified in the competitive revision Notice of Special Interest (NOSI). |
| AACR Early-Career Scholar in the Field of Cancer Research Awards | 24 Nov 2026 | Travel Funds | American Association for Cancer Research (AACR) | Early Career and Emerging in Field, Graduate Student, and Pre-doc |
Click for detailsThe American Association for Cancer Research (AACR) is extremely pleased to announce the availability of scholar awards in cancer research for full-time eligible scientists wishing to participate in AACR Annual Meetings and AACR special conferences. The purposes of this award program are to increase the scientific knowledge base of early-career scientists and to encourage them to pursue careers in cancer research. |
| Mission Boost Grants (MBG) | 01 Dec 2026 | $135,000 - $545,000 | American Cancer Society (ACS) | Early Career / Mid-Career |
Click for detailsMission Boost Grants (MBG) are designed to support research projects that specifically focus on translation to human testing. MBGs are opportunities for independent investigators at all levels to apply for additional, or "boost," resources for innovative, clinical-enabling projects. MBGs offer 2 stages of funding:Stage Irequires the investigator to develop outcome-specific, unequivocal milestones that reduce the risks of studying a new drug, device, or procedure in patients.Stage IIsupports testing in cancer patients. |
| Postdoctoral Fellowships | 01 Dec 2026 | $66,000 - $70,000 over 3 years | American Cancer Society (ACS) | Postdoctoral Fellowship |
Click for detailsPostdoctoral Fellowships (PF) support new investigators in research training programs to position them for independent careers in cancer research. As part of their evaluation, peer reviewers consider how well the fellowship will broaden the applicant’s research training and experience. |
| Research Scholar Grants | 01 Dec 2026 | varies to reflect the needs of the project | American Cancer Society (ACS) | Early Career and Emerging in Field |
Click for detailsResearch Scholar Grants (RSG) provide support for independent, self-directed researchers. Applicants' institutions must provide space and other resources customary for independent investigators. Grant proposals are investigator-initiated and may pursue questions across the cancer research continuum, as long as they fit within an American Cancer Society (ACS) priority research area. These grants typically contribute to the cost of salaries, consumable supplies, and other miscellaneous items required in the research. |
| Clinical Innovator Grant | 01 Dec 2026 | $1,000,000 | Cancer Research Institute | Early Career / Mid-Career |
Click for detailsThe CRI Clinical Innovator supports pioneering immunotherapy clinical trials designed and led by academic researchers. These investigator-initiated studies are vital to improving patient outcomes, addressing areas of high unmet need, and generating critical mechanistic insights that can guide the future of cancer treatment. |
| CRI Clinic and Laboratory Integration Program | 01 Dec 2026 | $300,000/yr for 2 years | Cancer Research Institute | Early Career / Mid-Career |
Click for detailsThe CRI Clinic and Laboratory Integration Program (CLIP) supports innovative investigations at the intersection of laboratory discovery and clinical application in cancer immunology. |
| NIH Research Software Engineer (RSE) Award (R50 Clinical Trials Not Allowed) | 04 Dec 2026 | $300,000 over 3 years | National Institutes of Health (NIH) | Early Career / Mid-Career |
Click for detailsThe purpose of this notice of funding opportunity (NOFO) is to provide salary support for exceptional Research Software Engineers (RSEs) that contribute their skills to the development and dissemination of biomedical, behavioral or health related software, tools, and algorithms as well as to the training of prospective users of these tools. |
| IUSE: Innovation in Two-Year College STEM Education (ITYC) | 09 Dec 2026 | varies to reflect the needs of the project | National Science Foundation (NSF) | Early Career / Mid-Career |
Click for detailsThrough the IUSE: Innovation in Two-Year College STEM Education (ITYC) program, the agency seeks to extend this effort by making an intentional investment in the country's two-year institutions of higher education, or two-year colleges. The twin goals of the ITYC program are to (1) center students in the effort to advance innovation, promote equitable outcomes and broaden participation for all students in STEM education at two-year colleges, and (2) enhance the capacity of two-year colleges to harness the talent and potential of their diverse student and faculty population through innovative disciplinary, multi-department, and college-wide efforts. These goals will be achieved by investing in projects at two-year colleges that contribute to student success in STEM-based foundational courses and academic pathways for both majors and non-majors. Project activities may be in any discipline that is currently supported by NSF funding, which includes the social, behavioral, and economic sciences. Collectively, projects in the ITYC program will make progress towards ensuring that two-year college students and faculty have the resources to fully participate in and contribute to the broader STEM enterprise. Aligned with the goals above, the ITYC program features two tracks: (1) A Focus on the Academic Experiences of Two-Year College Students and (2) Leveraging Institutional Strengths and Innovation. |
| EPSCoR Research Infrastructure Improvement-Focused EPSCoR Collaborations Program (RII-FEC) | 15 Dec 2026 | varies to reflect the needs of the project | National Science Foundation (NSF) | Early Career / Mid-Career |
Click for detailsThe Established Program to Stimulate Competitive Research (EPSCoR) is designed to fulfill the mandate of the National Science Foundation (NSF) to promote scientific progress nationwide. EPSCoR eligibility status is yearly updated and reported in the EPSCoR website (see EPSCoR eligibility). Through this program, NSF establishes partnerships with government, higher education, and industry that are designed to affect sustainable improvements in a jurisdiction's research infrastructure, Research and Development (R&D) capacity, and hence, its R&D competitiveness. The RII-FEC program (formerly known as "EPSCoR Track-2 program") builds inter-jurisdictional collaborative teams of EPSCoR investigators in Science, Technology, Engineering, and Mathematics (STEM) focus areas consistent with the current National Science Foundation Strategic Plan. Projects are investigator-driven and must include researchers from at least two EPSCoR eligible jurisdictions with complementary expertise and resources necessary to address challenges, which neither party could address as well or as rapidly independently. RII-FEC projects have a comprehensive and integrated vision to drive discovery and build sustainable STEM capacity that exemplifies individual, institutional, geographic, and disciplinary diversity. The projects' STEM research and education activities seek to broaden participation through the strategic inclusion and integration of all individuals, institutions, and sectors. Additionally, EPSCoR recognizes that the development of early-career faculty from backgrounds that are traditionally underrepresented in STEM fields is critical to sustaining and advancing research capacity. The integration and inclusion of Minority-Serving Institutions (MSIs), women's colleges, Primarily Undergraduate Institutions (PUIs), and two-year colleges is a critical component of this sustainable STEM capacity. |
| Interdisciplinary Minority Fellowship Program | 15 Jan 2027 | varies to reflect the needs of the project | American Psychological Association (APA) | Graduate Student or Pre-doc |
Click for detailsThe fellowship is directly related to efforts to reduce health disparities among ethnic minorities in the U.S. by filling a crucial need for mental health professionals in psychology, nursing, social work, marriage and family therapy, mental health counseling, and substance use and addictions counseling. The MFP selects individuals with promise and a commitment to careers that address behavioral health services needs of ethnic minorities. Thus, the IMFP has two target populations at the center of its efforts: the members of ethnic and racial minorities in need of behavioral health services and ethnic minority graduate students in the six represented disciplines. |
| Improving Undergraduate STEM Education: Directorate for STEM Education (IUSE: EDU) | 20 Jan 2027 | varies to reflect the needs of the project | National Science Foundation (NSF) | Early Career / Mid-Career |
Click for detailsThe National Science Foundation (NSF) plays a leadership role in developing and implementing efforts to enhance and improve STEM education in the United States. Through the NSF Improving Undergraduate STEM Education (IUSE) initiative, the agency continues to make a substantial commitment to the highest caliber undergraduate STEM education through a Foundation-wide framework of investments. The IUSE: EHR is a core NSF STEM education program that seeks to promote novel, creative, and transformative approaches to generating and using new knowledge about STEM teaching and learning to improve STEM education for undergraduate students. The program is open to application from all institutions of higher education and associated organizations. NSF places high value on educating students to be leaders and innovators in emerging and rapidly changing STEM fields as well as educating a scientifically literate public. In pursuit of this goal, IUSE: EHR supports projects that seek to bring recent advances in STEM knowledge into undergraduate education, that adapt, improve, and incorporate evidence-based practices into STEM teaching and learning, and that lay the groundwork for institutional improvement in STEM education. In addition to innovative work at the frontier of STEM education, this program also encourages replication of research studies at different types of institutions and with different student bodies to produce deeper knowledge about the effectiveness and transferability of findings. IUSE: EHR also seeks to support projects that have high potential for broader societal impacts, including improved diversity of students and instructors participating in STEM education, professional development for instructors to ensure adoption of new and effective pedagogical techniques that meet the changing needs of students, and projects that promote institutional partnerships for collaborative research and development. IUSE: EHR especially welcomes proposals that will pair well with the efforts ofNSF INCLUDESto develop STEM talent from all sectors and groups in our society. For all the above objectives, the National Science Foundation invests primarily in evidence-based and knowledge-generating approaches to understand and improve STEM learning and learning environments, improve the diversity of STEM students and majors, and prepare STEM majors for the workforce. In addition to contributing to STEM education in the host institution(s), proposals should have the promise of adding more broadly to our understanding of effective teaching and learning practices. The IUSE: EHR program features two tracks: (1) Engaged Student Learning and (2) Institutional and Community Transformation. |
| Development of Collaborative Research Facilities or Research-Resource Facilities (C06 Clinical Trial Not Allowed) | 25 Jan 2027 | varies to reflect the needs of the project | National Institutes of Health (NIH) | Early Career / Mid-Career |
Click for detailsThis Notice of Funding Opportunity (NOFO) solicits applications to develop shared-use research facilities or research-supporting facilities that enable collaborative research and benefit broad research communities at large. The NOFO supports two existing construction programs: the Biomedical Research Facilities (BRF) program and the HIV/AIDS Research Facilities (HRF) program. The BRF program supports the construction or modernization of biomedical research facilities that advance basic, translational, clinical, or behavioral science research in all areas. Intended facilities include shared research spaces, core facilities, biorepositories, or other shared-use resource facilities that serve a broad scientific community with a significant, long-term impact on biomedical research. |
| Cancer Advancement through Partnerships in Research and Infrastructure (CAPRI) (U54 Clinical Trial Optional) | 25 Jan 2027 | varies to reflect the needs of the project | National Institutes of Health (NIH) | Not Applicable |
Click for detailsThis is a Notice of Funding Opportunity (NOFO) for a Limited Competition that invites applications from eligible organizations to apply. The purpose of the CAPRI Program is to establish and strengthen comprehensive and mutually beneficial partnerships between Resource Limited Institutions (RLIs) and NCI-designated Cancer Centers (CCs) to accelerate collaborative and innovative cancer. Through strategic capacity building, CAPRI supports the development and expansion of sustainable research programs at partnering institutions, enhances the quality and competitiveness of cancer research programs, and promotes the integration of complementary expertise and resources across institutions. Joint research projects conducted primarily at RLIs may span any area of cancer research and are intended to strengthen institutional research capacity and scientific productivity. The institutions in each partnership are expected to work collaboratively to: Strengthening cancer research capacity at Resource Limited Institutions (RLIs) by developing cancer research, enhancing institutional research infrastructure and competitiveness, and promoting the career development of ESIs and trainees. Developing and implementing coordinated cancer-related outreach and education initiatives that are integrated with the partnership's research priorities and extending the benefits of scientific advances to communities nationwide. To underscore their commitment to the partnership, linked applications from each partnering institution are required. |
| National Centers for Cryo-electron Tomography (cryoET) (R24 -Clinical Trial Not Allowed) | 26 Jan 2027 | varies to reflect the needs of the project | National Institutes of Health (NIH) | Early Career / Mid-Career |
Click for detailsThis Notice of Funding Opportunity (NOFO) is for support of National Centers for Cryoelectron Tomography (CryoET) to provide nationwide access to advanced cryoET instrumentation and technical support, and to assist investigators in acquiring the skills needed to perform cryoET studies. |
| Maximizing Investigators' Research Award (MIRA) (R35 - Clinical Trial Optional) | 27 Jan 2027 | $275,000/yr for 5 years | National Institutes of Health (NIH) | Early Career / Mid-Career |
Click for detailsThe Maximizing Investigators' Research Award (MIRA) provides support for individual investigators for research within the scientific mission of NIGMS via a single grant to achieve the following: Increase the stability of funding for NIGMS-supported investigators, which could enhance their ability to take on ambitious scientific projects and approach problems more creatively; Increase flexibility for investigators to follow important new research directions within the NIGMS mission as opportunities arise, rather than being bound to specific aims proposed in advance of the studies; More widely distribute funding among the nation's highly talented and promising investigators to increase overall scientific productivity and the chances for important breakthroughs; Reduce the time spent by researchers writing and reviewing grant applications, allowing them to spend more time conducting research; Reduce the administrative burden associated with a PD/PI managing multiple NIGMS research grants; and Enable PD(s)/PI(s) to devote more time and energy to mentoring junior scientists in a more stable research environment. This NOFO invites applications from eligible NIGMS-funded investigators and from New Investigators proposing research that is aligned with NIGMS' scientific mission. |
| Biomedical Research Environment and Sponsored Programs Administration Development (BRE-SPAD) Program (UC2- Clinical Trial Not Allowed) | 27 Jan 2027 | varies to reflect the needs of the project | National Institutes of Health (NIH) | Early Career / Mid-Career |
Click for detailsThe Biomedical Research Environment & Sponsored Programs Administration Development (BRE-SPAD) Program aims to promote broad participation in biomedical research by supporting resource-limited institutions to conduct research, enhance their research environments, and increase sponsored programs administration capacity. This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP). Components of Participating Organizations: National Institute of General Medical Sciences (NIGMS) National Eye Institute (NEI) National Institute on Aging (NIA) National Institute on Alcohol Abuse and Alcoholism (NIAAA) National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) National Institute of Dental and Craniofacial Research (NIDCR) National Institute on Drug Abuse (NIDA) National Institute of Mental Health (NIMH) National Institute of Neurological Disorders and Stroke (NINDS) National Center for Complementary and Integrative Health (NCCIH) All applications to this funding opportunity announcement should fall within the mission of the Institutes/Centers. The following NIH Offices may co-fund applications assigned to those Institutes/Centers. Office of Data Science Strategy (ODSS) |
| Bioengineering Partnerships with Industry (U01 Clinical Trial Optional) | 27 Jan 2027 | varies to reflect the needs of the project | National Institutes of Health (NIH) | Early Career / Mid-Career |
Click for detailsThis Funding Opportunity Announcement (FOA) solicits applications from research partnerships formed by academic and industrial investigators to accelerate the development and adoption of promising bioengineering tools and technologies that can address important biomedical problems. The objectives are to establish these tools and technologies as robust, well-characterized solutions that fulfill an unmet need and are capable of enhancing our understanding of life science processes or the practice of medicine. Awards will focus on supporting multidisciplinary teams that apply an integrative, quantitative bioengineering approach to developing technologies. The goal of the program is to support technological innovations that deliver new capabilities which can realize meaningful solutions within 5 — 10 years. Components of Participating Organizations: National Institute of Biomedical Imaging and Bioengineering (NIBIB) National Eye Institute (NEI) National Institute on Aging (NIA) National Cancer Institute (NCI) |
| Limited Competition: NCATS Clinical and Translational Science Award (CTSA) Program Research Education Grants Programs (R25 - Clinical Trial Not Allowed) | 28 Jan 2027 | varies to reflect the needs of the project | National Institutes of Health (NIH) | Mid-Career to Established in Field |
Click for detailsThe NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this NOFO will support educational activities with a primary focus on: Research Experiences This NOFO is part of a required set of companion applications: the Clinical and Translational Science Award (UM1) and companion Institutional Career Development Award (K12). The remaining NOFOs in the suite are optional and include the Ruth L. Kirschstein National Research Service Award (NRSA) institutional training programs (T32 predoctoral and T32 postdoctoral), the Research Education Grant (R25), and the Specialized Innovation Program (RC2). These optional NOFOs are only available to CTSA Program UM1 applicants and award recipients. Applications to the companion NOFOs cannot be awarded until an award has been issued for the UM1. |
| Biological Anthropology Program Senior Research Awards (BA-SR) | 31 Jan 2027 | varies to reflect the needs of the project | National Science Foundation (NSF) | Early Career / Mid-Career |
Click for detailsThe Biological Anthropology Program seeks to advance scientific knowledge about the processes that have shaped biological diversity in living and fossil humans and their primate relatives through support of basic research on human and primate evolution, biological variation, and interactions between biology, behavior, and culture. The program supports a portfolio of research that demonstrates engagement with biological anthropological and evolutionary theory; includes diverse and interdisciplinary methods in field, laboratory and computational settings; encompasses multiple levels of analysis (e.g., molecular, organismal, population, ecosystem) and time scale analysiss from the short-term to evolutionary; and considers the ethical implications and societal impacts of the research. The program also supports a wide range of broader impact activities as part of research grants, including research outcomes with inherent benefit to society, efforts to broaden participation in science, technology, engineering, and mathematics (STEM) research, training and outreach activities and other evidence-based activities developed within the context of the mission, goals, and resources of the organizations and people involved. |
| Opportunities for Collaborative Research at the NIH Clinical Center (U01 Clinical Trial Optional) | 05 Feb 2027 | $500,000/yr for 2 years | National Institutes of Health (NIH) | Early Career / Mid-Career |
Click for detailsThe goal of this program is to support collaborative translational research projects aligned with NIH efforts to enhance the translation of basic biological discoveries into clinical applications that improve health. It encourages high quality science demonstrating the potential to result in understanding an important disease process or lead to new therapeutic interventions, diagnostics, or prevention strategies within the research interests and priorities of the participating NIH Institutes/Centers (ICs).Specifically, the program seeks to broaden and strengthen patient-centric translational research collaborations between basic and clinical researchers both within and outside NIH to accelerate and enhance translational science by promoting partnerships between NIH intramural investigators (e.g., those conducting research within the labs and clinics of the NIH) and extramural investigators (e.g., those conducting research in labs outside the NIH), and by providing support for extramural investigators to take advantage of the unique research opportunities available at the NIH Clinical Center by conducting clinical research projects in collaboration with NIH intramural investigators. |
| Investigator Initiated Research in Computational Genomics and Data Science (R01 Clinical Trial Not Allowed) | 05 Feb 2027 | $500,000/yr for 5 years | National Institutes of Health (NIH) | Early Career / Mid-Career |
Click for detailsThe purpose of this renewing Notice of Funding Opportunity (NOFO) is to support investigator-initiated research efforts fostering innovation in computational genomics, data science, statistics, bioinformatics, and data visualization and exploration. This NOFO supports development of innovative analytical methodologies and approaches and early-stage tools and software for genomics, rather than incremental advances or modification and application of existing approaches. Projects should be enabling for genomics research, broadly applicable to human health and disease, and generalizable across diseases and biological systems. Examples of research topics that may be appropriate for this NOFO include development of innovative computational, bioinformatics, statistical, or analytical approaches, tools, or software, such as: Tools for visualization of large genomic data sets Development of genetically informed causal inference methods Machine learning and artificial intelligence (AI) methods for genomics research, including development of generative AI and estimation of model power, validation and benchmarking Privacy-preserving technologies to access and compute on controlled-access human genomic, phenotypic, and clinical research data Improving efficiency and scalability of compute-intensive genomic data analysis applications, including novel methods to reduce the size of large models or cross-model training Tools to improve synergy between genomic data generation and computation, including integrating AI in experimental workflows to automate or optimize data gathering Methodology development for federated learning on distributed genomic data, computing resources, and models from multiple sites |
| Basic Research in Cancer Health Disparities (R01 Clinical Trial Not Allowed) | 05 Feb 2027 | varies to reflect the needs of the project | National Institutes of Health (NIH) | Early Career / Mid-Career |
Click for detailsThis Notice of Funding Opportunity (NOFO) encourages grant applications from investigators interested in conducting basic, mechanistic research into the biological/genetic causes of cancer health disparities. These research project grants (R01) will support innovative studies designed to investigate biological/genetic contributors of cancer health disparities, such as (1) mechanistic studies of biological factors associated with cancer health disparities, including those related to basic research in cancer biology or cancer prevention strategies, (2) the development and testing of new methodologies and models, and (3) secondary data analyses. This NOFO is also designed to aid and facilitate the growth of a nationwide cohort of scientists with a high level of basic research expertise in cancer health disparities research who can expand available resources and tools, such as biospecimens, patient derived models, and methods that are necessary to conduct basic research in cancer health disparities. |
| Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Optional) | 05 Feb 2027 | $499,000/yr for 5 years | National Institutes of Health (NIH) | Early Career / Mid-Career |
Click for detailsThe purpose of this Notice of Funding Opportunity (NOFO) Announcement is to stimulate efforts to translate scientific discoveries and engineering developments into methods or tools that address problems in basic research to understand disease, or in applied research to assess risk, detect, prevent, diagnose, treat, and/or manage disease. The rationale is to deliver new capabilities to meet evolving requirements for technologies and methods relevant to the advance of research and delivery of care in pre-clinical, clinical and non-clinical settings, domestic or foreign, for conditions and diseases within the missions of participating institutes.This NOFO specifies a partnership structure that is expected to help bridge gaps in knowledge and experience by engaging the strengths of academic, industrial, and other investigators. The partners on each application should establish an inter-disciplinary, multi-institutional research team to work in strategic alliance to implement a coherent strategy to develop and translate a solution to their chosen problem. They are expected to plan, design, and validate that the solution will be suitable for end users. Each partnership should include at least one academic and one industrial organization. Each partnership should plan to transition a technology, method, assay, device, and/or system from a demonstration of possibility to a status useful in the chosen setting. Funding may be requested to enhance, adapt, optimize, validate, and otherwise translate technologies that address problems in biology, pathology, risk assessment, diagnosis, treatment, and/or monitoring of disease status. |
| Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Not Allowed) | 05 Feb 2027 | $499,000/yr for 5 years | National Institutes of Health (NIH) | Early Career / Mid-Career |
Click for detailsThe purpose of this Notice of Funding Opportunity (NOFO) is to stimulate efforts to translate scientific discoveries and engineering developments into methods or tools that address problems in basic research to understand disease, or in applied research to assess risk, detect, prevent, diagnose, treat, and/or manage disease. The rationale is to deliver new capabilities to meet evolving requirements for technologies and methods relevant to the advance of research and delivery of care in pre-clinical, clinical and non-clinical settings, domestic or foreign, for conditions and diseases within the missions of participating institutes. This NOFO specifies a partnership structure that is expected to help bridge gaps in knowledge and experience by engaging the strengths of academic, industrial, and other investigators. The partners on each application should establish an inter-disciplinary, multi-institutional research team to work in strategic alliance to implement a coherent strategy to develop and translate a solution to their chosen problem. They are expected to plan, design, and validate that the solution will be suitable for end users. Each partnership should include at least one academic and one industrial organization. Each partnership should plan to transition a technology, method, assay, device, and/or system from a demonstration of possibility to a status useful in the chosen setting. Funding may be requested to enhance, adapt, optimize, validate, and otherwise translate technologies that address problems in biology, pathology, risk assessment, detection, diagnosis, treatment, and/or monitoring of disease status. This NOFO defines "innovation" as likelihood to deliver a new capability to end users. |
| Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional) | 05 Feb 2027 | $250,000/yr for 5 years | National Institutes of Health (NIH) | Early Career / Mid-Career |
Click for detailsThis notice of funding opportunity (NOFO) encourages applications for research in cancer control and population sciences. The overarching goal is to provide support to promote research efforts on novel scientific ideas that have the potential to substantially advance cancer research in statistical and analytic methods, epidemiology, cancer survivorship, cancer-related behaviors and behavioral interventions, health care delivery, digital health and data science, and implementation science. |
| Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional) | 05 Feb 2027 | varies to reflect the needs of the project | National Institutes of Health (NIH) | Early Career / Mid-Career |
Click for detailsThrough this notice of funding opportunity (NOFO), the National Cancer Institute (NCI) invites applications for investigator-initiated studies addressing mechanisms by which incretin mimetics, specifically glucagon-like peptide (GLP)-1 or dual GLP-1/ glucose-dependent insulinotropic polypepide (GIP)-1 receptor agonists (RAs), impact cancer risk. The focus on these agents is due to their reported effects on thyroid, prostate and other cancer risks, and the generally more favorable efficacy and side effect profile compared to other classes of incretin mimetics. In addition, this NOFO seeks to draw in talented scientists to the cancer biology field who may study incretin mimetic effects on diseases other than cancer. Investigators wishing to study incretin mimetics other than GLP-1 RAs or GLP-1/GIP-1 RAs, such as dipeptidyl peptidase (DPP)-4 inhibitors, must justify why the agent(s) they propose to study are more effective and/or have a more favorable side effect profile than GLP-1 or GLP-1/GIP-1 RAs. Route of agent administration (oral vs. other) is, by itself, not an adequate justification. |
| Interventions to Address Disparities in Liver Diseases and Liver Cancer (R01 - Clinical Trials Optional) | 05 Feb 2027 | varies to reflect the needs of the project | National Institutes of Health (NIH) | Early Career / Mid-Career |
Click for detailsThis initiative will support multi-level and/or multi-domain intervention research to reduce disparities in liver diseases and liver cancer among populations who experience health disparities in the United States (U.S.). |
| Mechanisms that Impact Cancer Risk after Bariatric Surgery (R01 Clinical Trial Optional) | 05 Feb 2027 | $500,000/yr for 5 years | National Institutes of Health (NIH) | Early Career / Mid-Career |
Click for detailsThrough this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites applications for support of investigator-initiated studies addressing mechanisms by which bariatric surgery impacts cancer risk and seeks to draw in talented scientists who study bariatric surgery to investigate its effects on cancer, rather than shorter term outcomes such as weight loss and diabetes. |
| Mechanisms that Impact Cancer Risk after Bariatric Surgery (R01 Clinical Trial Optional) | 05 Feb 2027 | $500,000/yr for 5 years | National Institutes of Health (NIH) | Early Career / Mid-Career |
Click for detailsThrough this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites applications for support of investigator-initiated studies addressing mechanisms by which bariatric surgery impacts cancer risk and seeks to draw in talented scientists who study bariatric surgery to investigate its effects on cancer, rather than shorter term outcomes such as weight loss and diabetes. |
| Molecular Imaging of Inflammation in Cancer (R01 Clinical Trial Not Allowed) | 05 Feb 2027 | $500,000/yr for 2 years | National Institutes of Health (NIH) | Early Career / Mid-Career |
Click for detailsThrough this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites research grant applications (R01) for the development and application of current and emerging molecular imaging methods to gain fundamental insights into cancer inflammationin vitro. The motivation for this initiative is the recognition that much of the current imaging research on inflammation in cancer relies heavily onin vitroandex vivomethods. These approaches have limited potential to provide significant insights into the dynamic interactions between cancer and inflammation. Utilizing molecular imaging probes in pre-clinical and clinical investigations allows for precise temporal resolution at molecular and cellular levels. This information is valuable for identifying and characterizing in vivo inflammatory cellular physiology in cancer and for detecting molecular changes in response to treatment. This NOFO encourages applications focused on developing integrated imaging approaches to investigate the role of inflammation in cancer through strong cross-discipline collaboration between cancer basic science researchers and imaging scientists. These collaborations are expected to advance the science and understanding of cancer inflammation interactions. |
| RFA: Cancer Health Research Centers (CHERCs) | 09 Feb 2027 | $1,650,000 over 4 years | American Cancer Society (ACS) | Early Career / Mid-Career |
Click for detailsAs part of the American Cancer Society (ACS) mission to promote fair and just opportunity to prevent, detect, treat, and survive cancer, we have created the Cancer Health Research Center (CHERC) program. CHERCs are designed to address cancer health disparities that affect local or regional communities. Priority will be given to Centers that focus on actionable, solution-based research designed to improve the health of the community and advance our goals for achieving health equity and reducing cancer mortality. |
| Hispanic-Serving Institutions: Enriching Learning, Programs, and Student Experiences | 11 Feb 2027 | varies to reflect the needs of the project | National Science Foundation (NSF) | Early Career / Mid-Career |
Click for detailsHispanic Serving Institutions (HSIs) are an important component of the nation's higher education ecosystem and play a critical role in realizing the National Science Board's vision for a more diverse and capable science and engineering workforce. Aligned with this vision and the NSF Strategic Plan, the goals of the NSF HSI Program are to: Enhance the quality of undergraduate science, technology, engineering, and mathematics (STEM) education at HSIs. Increase the recruitment, retention, and graduation rates of students pursuing associates or baccalaureate degrees in STEM at HSIs. Meeting these goals requires institutions to understand and embrace their students' strengths, challenges, and lived experiences. While this can happen in many ways and across many parts of an institution, the Hispanic Serving Institutions: Enriching Learning, Programs, and Student Experiences (HSI:ELPSE) solicitation is specifically focused on studying and improving the student experience in the following settings: STEM courses, particularly for students pursuing STEM degrees; Certificate, minor, and/or degree programs; Academic departments or divisions; and Schools and colleges that represent a part of the entire institution (e.g., a School of Engineering or a College of Natural Sciences). |
| Institutional Mentored Career Development Award (Parent K12) (Clinical Trials Not Allowed) | 12 Feb 2027 | varies to reflect the needs of the project | National Institutes of Health (NIH) | Not Applicable |
Click for detailsThe National Institutes of Health (NIH) invite applications for the Institutional Mentored Career Development grants. These support career development programs designed to prepare later stage postdoctoral fellows and junior faculty scholars who have made a commitment to an independent research career for their career advancement and transition to independence. Supported scholars will have "protected time" to engage in intensive, mentored research career development experiences in the fields of biomedical and behavioral research. |
| NHLBI Career Transition Award for Intramural Postdoctoral Fellows and Research Trainees (K22 Independent Clinical Trial Not Allowed) | 12 Feb 2027 | varies to reflect the needs of the project | National Institutes of Health (NIH) | Early Career and Emerging in Field |
Click for detailsThe purpose of the NHLBI Career Transition Award (K22) program is to provide highly qualified postdoctoral fellows and other doctoral-level researchers currently in training in the NHLBI Division of Intramural Research with the opportunity to transition their research programs to extramural institutions as junior investigators. To achieve these objectives, the NHLBI Career Transition Award will support two phases of research: a mentored intramural phase (up to two years) and an extramural phase (three years), for a total of five years of combined support. Transition from the intramural phase of support to the extramural phase is not automatic. Approval of the transition will be based on the success of the awardee's research program during the mentored phase as determined by an NHLBI progress review, which will include an evaluation of a research plan to be carried out at the extramural institution. |
| Paul Calabresi career development award for clinical oncology (K12 clinical trial optional) | 12 Feb 2027 | $50,000 - $750,000/yr for 5 years | National Institutes of Health (NIH) | Mid-Career to Established in Field |
Click for detailsThe goal of the Paul Calabresi Career Development Award for Clinical Oncology (PCACO) is to increase the number of clinician-scientists trained in clinical and translational cancer research, and to promote their career development as cancer researchers. |
| Mechanisms that Impact Cancer Risk after Bariatric Surgery (R21 Clinical Trial Not Allowed) | 16 Feb 2027 | $275,000 over 2 years | National Science Foundation (NSF) | Early Career / Mid-Career |
Click for detailsThrough this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites applications for support of investigator-initiated studies addressing mechanisms by which bariatric surgery impacts cancer risk, and seeks to draw in talented scientists who study bariatric surgery to investigate its effects on cancer, rather than shorter-term outcomes such as weight loss and diabetes. The goal of this NOFO is to support proof of concept studies for feasibility and exploratory development. Feasibility must not have already been developed in the literature or with preliminary data. |
| Investigator Initiated Research in Computational Genomics and Data Science (R21 Clinical Trial Not Allowed) | 16 Feb 2027 | varies to reflect the needs of the project | National Institutes of Health (NIH) | Early Career / Mid-Career |
Click for detailsThe purpose of this renewing Notice of Funding Opportunity (NOFO) is to support investigator-initiated research efforts fostering innovation in computational genomics, data science, statistics, bioinformatics, and data visualization and exploration. This NOFO supports development of innovative analytical methodologies and approaches and early-stage tools and software for genomics, rather than incremental advances or modification and application of existing approaches. Projects should be enabling for genomics research, broadly applicable to human health and disease, and generalizable across diseases and biological systems. Examples of research topics that may be appropriate for this NOFO include development of innovative computational, bioinformatics, statistical, or analytical approaches, tools, or software, such as: Tools for visualization of large genomic data sets Development of genetically informed causal inference methods Machine learning and artificial intelligence (AI) methods for genomics research, including development of generative AI and estimation of model power, validation and benchmarking Privacy-preserving technologies to access and compute on controlled-access human genomic, phenotypic, and clinical research data Improving efficiency and scalability of compute-intensive genomic data analysis applications, including novel methods to reduce the size of large models or cross-model training Tools to improve synergy between genomic data generation and computation, including integrating AI in experimental workflows to automate or optimize data gathering Methodology development for federated learning on distributed genomic data, computing resources, and models from multiple sites Applicants are encouraged to propose creative and innovative research topics that go beyond the examples listed above. |
| Basic Research in Cancer Health Disparities (R21 Clinical Trial Not Allowed) | 16 Feb 2027 | $275,000 over 2 years | National Institutes of Health (NIH) | Early Career / Mid-Career |
Click for detailsThis Notice of Funding Opportunity (NOFO) encourages grant applications from investigators interested in conducting basic research studies into the biological/genetic causes and mechanisms of cancer health disparities. These awards will support pilot and feasibility studies designed to investigate biological/genetic contributors of cancer health disparities, such as (1) mechanistic studies of biological factors associated with cancer health disparities, (2) the development and testing of new methodologies and models, and (3) secondary data analyses. This NOFO is also designed to aid and facilitate the growth of a nationwide cohort of scientists with a high level of basic research expertise in cancer health disparities research who can expand available resources and tools, such as biospecimens, patient derived models and methods that are necessary to conduct basic research in cancer health disparities. In addition, the NOFO will further the development of scientific areas, providing support for early-stage exploratory projects that lead to future in-depth mechanistic studies (such as R01 projects) of the biology of cancer health disparities. |
| Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed) | 16 Feb 2027 | $275,000 over 2 years | National Institutes of Health (NIH) | Early Career / Mid-Career |
Click for detailsThrough this notice of funding opportunity (NOFO), the National Cancer Institute (NCI) invites applications for investigator-initiated studies addressing mechanisms by which incretin mimetics, specifically glucagon-like peptide (GLP)-1 or dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP)-1 receptor agonists (RAs), impact cancer risk. The focus on these agents is due to their reported effects on thyroid, prostate and other cancer risks, and the generally more favorable efficacy and side effect profile compared to other classes of incretin mimetics. In addition, this NOFO seeks to draw in talented scientists to the cancer biology field who may study incretin mimetic effects on diseases other than cancer. |
| Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Optional) | 16 Feb 2027 | $275,000 over 2 years | National Institutes of Health (NIH) | Early Career / Mid-Career |
Click for detailsThe purpose of this engineering-oriented notice of funding opportunity (NOFO) announcement is to encourage submissions of exploratory/developmental Bioengineering Research Grant (EBRG) applications to demonstrate feasibility and potential utility of new capabilities or improvements in quality, speed, efficacy, operability, costs, and/or accessibility of solutions to problems in basic biomedical, pre-clinical, or clinical research, clinical care delivery, or accessibility. This NOFO will support clinical trials that test functionality or validate performance in the chosen setting. Applications that propose phase III clinical trials are not sought by and will not be supported through this NOFO. |
| Developing novel theory and methods for understanding the genetic architecture of complex human traits (R21 Clinical Trial Not Allowed) | 16 Feb 2027 | $275,000 over 2 years | National Institutes of Health (NIH) | Early Career / Mid-Career |
Click for detailsThe goal of this NOFO is to support applications for novel theory and methods development that enable better understanding of how genetic and non-genetic factors contribute to complex trait variation across individuals, families, and populations. Approaches should account for interdependencies across scales of biological, social, and ecological organization, make extensive use of theory, modeling, and validation with available large-scale datasets, and may be interdisciplinary drawing from the natural and social sciences. |
| NCI Pathway to Independence Award (K99/R00 Clinical Trial Not Allowed) | 17 Feb 2027 | varies to reflect the needs of the project | National Institutes of Health (NIH) | Early Career and Emerging in Field |
Click for detailsThe goal of the NCI Pathway to Independence Award (K99/R00) program is to facilitate a timely transition of talented postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help awardees to launch competitive, independent research careers. |
| NCI Pathway to Independence Award (K99/R00 Clinical Trial Required) | 17 Feb 2027 | varies to reflect the needs of the project | National Institutes of Health (NIH) | Early Career and Emerging in Field |
Click for detailsThe goal of the NCI Pathway to Independence Award (K99/R00) program is to facilitate a timely transition of talented postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help awardees to launch competitive, independent research careers. |
| NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00 - Independent Clinical Trial Required) | 17 Feb 2027 | varies to reflect the needs of the project | National Institutes of Health (NIH) | Early Career and Emerging in Field |
Click for detailsThe purpose of the NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00) program is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. This program is designed for postdoctoral fellows with research and/or clinical doctoral degrees who do not require an extended period of mentored research training beyond their doctoral degrees. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent tenure-track (or equivalent) faculty positions. The program will provide independent NCI research support during this transition to help awardees launch competitive, independent research careers. Researchers in the scientific areas of cancer control, cancer prevention and cancer data sciences are especially encouraged to work with their institutions to apply. |
| NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00 - Independent Clinical Trial Not Allowed) | 17 Feb 2027 | varies to reflect the needs of the project | National Institutes of Health (NIH) | Early Career and Emerging in Field |
Click for detailsThe purpose of the NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00) program is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. This program is designed for postdoctoral fellows with research and/or clinical doctoral degrees who do not require an extended period of mentored research training beyond their doctoral degrees. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent tenure-track (or equivalent) faculty positions. The program will provide independent NCI research support during this transition to help awardees launch competitive, independent research careers. Researchers in the scientific areas of cancer control, cancer prevention and cancer data sciences are especially encouraged to work with their institutions to apply. |
| The NCI Worta McCaskill-Stevens Career Development Award for Community Oncology and Prevention Research (K12 Clinical Trial Optional) | 18 Feb 2027 | varies to reflect the needs of the project | National Institutes of Health (NIH) | Mid-Career to Established in Field |
Click for detailsThe purpose of the NCI Worta McCaskill-Stevens Career Development Award for Community Oncology and Prevention Research (K12) is to support the training of clinical scientists in community cancer prevention, screening, intervention, control, and treatment research. Special emphasis is placed on training clinical scientists whose career goal is to improve the care and outcomes of minority health populations and populations with health disparities that are underrepresented in clinical research by increasing their access to and representation as human subjects in cancer clinical trials using an equity lens. This Notice of Funding Opportunity (NOFO) allows the appointment of Scholars proposing to serve as the lead investigator of an independent community-based clinical trial; proposing to increase the integration of cancer health disparities research questions into clinical trials; or proposing a separate ancillary study to an existing prevention, screening, intervention, control or treatment trial; or proposing to gain research experience in a community-based clinical trial led by another investigator; or proposing to serve as leader of innovative clinical trial approaches that expand engagement of minority health populations and populations with health disparities that are underrepresented as human subjects in cancer clinical trials, as part of their research and career development. |
| Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools (R15 Clinical Trial Not Allowed) | 25 Feb 2027 | $375,000 over 3 years | National Institutes of Health (NIH) | Early Career / Mid-Career |
Click for detailsThe purpose of the Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools is to support small scale research grants at institutions that do not receive substantial funding from the NIH, with an emphasis on providing biomedical research experiences primarily for health professional, undergraduate and graduate students and enhancing the research environment at applicant institutions. |
| Cancer Prevention and Control Clinical Trials Planning Grant Program (U34 Clinical Trials Optional) | 25 Feb 2027 | $450,000 - $600,000 over 3 years | National Institutes of Health (NIH) | Early Career / Mid-Career |
Click for detailsThrough this notice of funding opportunity (NOFO), the National Cancer Institute (NCI) intends to facilitate well planned clinical trials across the cancer prevention and control spectrum aimed at improving prevention/ interception, cancer-related health behaviors, screening, early detection, healthcare delivery, management of treatment-related symptoms, supportive care, and the long-term outcomes of cancer survivors. Although the scientific literature or preliminary data may provide the rationale for conducting a clinical trial, investigators often lack critical information about the study population, accrual challenges, intervention, outcome/ endpoints, data/statistical challenges or operational risks necessary to finalize the trial protocol completely. These information gaps can result in multiple protocol changes before and after trial start-up, leading to the need for additional time and expenses that may prevent study completion. Further, the suitability and feasibility of new trial designs, which minimize infrastructure and reduce costs may need to be tested in the context of a particular intervention, at-risk group, symptom or venue. Preparatory studies may fill information gaps and address unknowns this can include a pilot/feasibility clinical trial if necessary, improving trial design and rigor. |
| Cancer Prevention and Control Clinical Trials Planning Grant Program (R34 Clinical Trials Optional) | 25 Feb 2027 | $450,000 - $600,000 over 3 years | National Institutes of Health (NIH) | Early Career / Mid-Career |
Click for detailsThrough this notice of funding opportunity (NOFO), the National Cancer Institute (NCI) intends to facilitate well planned clinical trials across the cancer prevention and control spectrum aimed at improving prevention/ interception, cancer-related health behaviors, screening, early detection, healthcare delivery, management of treatment-related symptoms, supportive care, and the long-term outcomes of cancer survivors. Although the scientific literature or preliminary data may provide the rationale for conducting a clinical trial, investigators often lack critical information about the study population, accrual challenges, intervention, outcome/ endpoints, data/statistical challenges or operational risks necessary to finalize the trial protocol completely. These information gaps can result in multiple protocol changes before and after trial start-up, leading to the need for additional time and expenses that may prevent study completion. Further, the suitability and feasibility of new trial designs, which minimize infrastructure and reduce costs may need to be tested in the context of a particular intervention, at-risk group, symptom or venue. Preparatory studies may fill information gaps and address unknowns this can include a pilot/feasibility clinical trial if necessary, improving trial design and rigor. |
| Mid-Career Advancement (MCA) | 01 Mar 2027 | varies to reflect the needs of the project | National Science Foundation (NSF) | Mid-Career to Established in Field |
Click for detailsThe MCA program offers an opportunity for scientists and engineers at the mid-career stage (see restrictions under Additional Eligibility Information) to substantively enhance and advance their research program and career trajectory. Mid-career scientists are at a critical career transition stage where they need to advance their research programs to ensure long-term productivity and creativity but are often constrained by service, teaching, or other activities that limit the amount of time devoted to research. MCA support is expected to help lift these constraints to reduce workload inequities and enable a more diverse scientific workforce (more women, persons with disabilities, and individuals from groups that have been underrepresented) at high academic ranks. The MCA program provides protected time, resources, and the means to gain new skills through synergistic and mutually beneficial partnerships, typically at an institution other than the candidate's home institution. Partners from outside the Principal Investigator's (PI) own sub-discipline or discipline are encouraged, but not required, to enhance interdisciplinary networking and convergence across science and engineering fields. Research projects that envision new insights on existing problems or identify new problems made accessible with cutting-edge methodology or expertise from other fields are encouraged. A key component of a successful MCA will be the demonstration that the PI's current research program could substantively benefit from the protected time, mentored partnership(s), and resources provided through this program, such that there is a substantial enhancement to the PI's research and career trajectory, enabling scientific and academic advancement not likely without this support. The MCA is the only cross-directorate NSF program specifically aimed at providing protected time and resources to established scientists and engineers targeted at the mid-career stage. Participating programs in the Directorates for Biological Sciences (BIO), Geosciences (GEO), Social, Behavioral and Economic Sciences (SBE), Education and Human Resources (EHR), and Technology, Innovation and Partnerships (TIP) will accept MCA proposals. To help identify the disciplinary program in which the MCA should be reviewed, PIs are urged to investigate the research areas supported by the different directorates and participating programs. |
| Clare Boothe Luce Program for Women in STEM | 02 Mar 2027 | $750,000 over 5 years | Clare Boothe Luce Program for Women in STEM | Early Career |
Click for detailsThe Clare Boothe Luce Program for Women in STEM is dedicated to increasing the participation of women in the sciences and engineering at every level of higher education. The program aims to transform STEM ecosystems across the United States by addressing the structural and cultural barriers that inhibit women's pursuit of and persistence in STEM fields, expanding educational opportunities for women in STEM, and advancing their leadership in the sciences. |
| NSF Scholarships in Science, Technology, Engineering, and Mathematics (S-STEM) | 02 Mar 2027 | $2,000,000 - $5,000,000/yr for 6 years | National Science Foundation (NSF) | Early Career / Mid-Career |
Click for detailsThe main goal of the S-STEM program is to enable academically talented, low-income students to pursue successful careers in promising STEM fields. Ultimately, the S-STEM program seeks to increase the number of academically promising low-income students who graduate with an S-STEM eligible degree and contribute to the American innovation economy with their STEM knowledge. Recognizing that financial aid alone cannot increase retention and graduation in STEM, the program provides awards to institutions of higher education (IHEs) not only to fund scholarships, but also to adapt, implement, and study evidence-based curricular and co-curricular[a] activities that have been shown to be effective in supporting recruitment, retention, transfer (if appropriate), student success, academic/career pathways, and graduation in STEM. To be eligible, scholars must be domestic low-income students with academic ability, talent, or potential and demonstrated unmet financial need who are enrolled in an associate, baccalaureate, or graduate degree program in an S-STEM eligible discipline. |
| Short Courses on Innovative Methodologies and Approaches in the Behavioral and Social Sciences (R25 Clinical Trials Not Allowed) | 08 Mar 2027 | varies to reflect the needs of the project | National Institutes of Health (NIH) | Early Career / Mid-Career |
Click for detailsThe NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this NOFO will support educational activities with a primary focus on: Courses for Skills Development Components of Participating Organizations: Office of Behavioral and Social Sciences Research (OBSSR) National Heart, Lung, and Blood Institute (NHLBI) National Institute on Deafness and Other Communication Disorders (NIDCD) National Institute of Dental and Craniofacial Research (NIDCR) National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) National Institute on Drug Abuse (NIDA) National Institute of Mental Health (NIMH) National Institute of Nursing Research (NINR) National Center for Complementary and Integrative Health (NCCIH) National Cancer Institute (NCI) All applications to this funding opportunity announcement should fall within the mission of the Institutes/Centers. The following NIH Offices may co-fund applications assigned to those Institutes/Centers. Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention (ODP) Office of Dietary Supplements (ODS) Office of Research on Women's Health (ORWH) |
| Cutting-Edge Basic Research Awards (CEBRA) (R21-Clinical Trial Optional) | 10 Mar 2027 | varies to reflect the needs of the project | National Institutes of Health (NIH) | Early Career / Mid-Career |
Click for detailsThe National Institute on Drug Abuse (NIDA) Cutting-Edge Basic Research Award (CEBRA) is designed to foster highly innovative or conceptually creative research related to the etiology, pathophysiology, prevention, or treatment of substance use disorders (SUDs). It supports high-risk and potentially high-impact research that is underrepresented or not included in NIDA's current portfolio that has the potential to transform SUD research. The proposed research should: 1. develop, and/or adapt, revolutionary techniques or methods for addiction research or that show promising future applicability to SUD research; and /or 2. test an innovative and significant hypothesis for which there are scant precedent or preliminary data and which, if confirmed, would transform current thinking. |